🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "huge turning point" in the fight against superbug strains of the bacteria, according to scientists.

An International Health Concern

Gonorrhoea infections are on the rise globally, with estimates suggesting over 82 million instances per year. Especially elevated rates are observed in Africa and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a record high, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune development in the face of rising global incidence, the spread of superbugs and the extremely scarce therapeutic options presently on offer.”

Medical experts are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has classified it as a "critical concern". Ongoing monitoring revealed that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Secure Clearance

One new antibiotic, also known as a brand name, was authorized by the US FDA in mid-December for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts believe that targeted use of this new drug will help hinder the development of resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, was also approved in concurrent days. This treatment, which is also used to treat UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin stemmed from a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to develop it.

“This approval represents a significant shift in the therapy of superbug gonorrhoea, which until now has been outpacing antibiotic development.”

Research Study Results and Global Access

According to results detailed in a major medical journal, the new drug cured over nine in ten of cases of the STI. This puts it on an comparable level with the current standard treatment, which involves an injection and a pill. The research enrolled nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the ability to make available and distribute the drug in a wide range of low-income and middle-income countries.

Doctors treating patients have expressed optimism. The availability of a easy-to-administer therapy of this kind is hailed as a "revolutionary step" for gonorrhoea control. This is viewed as crucial to reduce the burden of the disease for patients and to halt the transmission of untreatable gonorrhoea around the world.